XML 22 R13.htm IDEA: XBRL DOCUMENT
v3.25.1

Supplementary Balance Sheet Information | 3 Months Ended
--- | ---
Mar. 31, 2025
Balance Sheet Related Disclosures [Abstract] |
Supplementary Balance Sheet Information | Note 5 – Supplementary Balance Sheet Information Property and equipment consist of the following (in thousands):
|  | As of |
|  | March 31, 2025 |  |  | December 31, 2024 |
Lab equipment |  | $ | 5,885 |  |  | $ | 5,854 |
Leasehold improvements |  |  | 28,208 |  |  |  | 28,192 |
Computer equipment |  |  | 1,338 |  |  |  | 1,305 |
Furniture and fixtures |  |  | 1,100 |  |  |  | 1,100 |
Software |  |  | 324 |  |  |  | 325 |
Vehicles |  |  | 97 |  |  |  | 97 |
Construction in process |  |  | 83 |  |  |  | 89 |
|  |  | 37,035 |  |  |  | 36,962 |
Less accumulated depreciation |  |  | (10,068 | ) |  |  | (9,134 | )
Total property and equipment, net |  | $ | 26,966 |  |  | $ | 27,828 |
Depreciation expense was $0.9 million for both the three months ended March 31, 2025 and 2024, respectively. Intangible assets, excluding goodwill, consist of the following (in thousands):
|  | March 31, 2025 |  |  | December 31, 2024 |
|  | Cost |  |  | Accumulated Amortization |  |  | Net Carrying Value |  |  | Cost |  |  | Accumulated Amortization |  |  | Net Carrying Value |
Intangible assets subject to amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Patents |  | $ | 1,923 |  |  | $ | (905 | ) |  | $ | 1,018 |  |  | $ | 1,940 |  |  | $ | (877 | ) |  | $ | 1,063 |
Purchased technology |  |  | 16,900 |  |  |  | (12,675 | ) |  |  | 4,225 |  |  |  | 16,900 |  |  |  | (12,206 | ) |  |  | 4,694 |
Intangible assets not subject to amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks |  |  | 117 |  |  |  | — |  |  |  | 117 |  |  |  | 117 |  |  |  | — |  |  |  | 117 |
Total |  | $ | 18,940 |  |  | $ | (13,580 | ) |  | $ | 5,360 |  |  | $ | 18,957 |  |  | $ | (13,083 | ) |  | $ | 5,874 |
Amortization expense related to definite-lived intangible assets was $0.5 million for both the three months ended March 31, 2025 and 2024, respectively. Future estimated amortization expense of intangible assets is (in thousands):
|  | As of March 31, 2025 |
Remainder of 2025 |  |  | 1,514 |
2026 |  |  | 2,000 |
2027 |  |  | 1,043 |
2028 |  |  | 93 |
2029 |  |  | 85 |
2030 and thereafter |  |  | 508 |
Total |  | $ | 5,243 |
Accrued liabilities consist of the following (in thousands):
|  | As of |
|  | March 31, 2025 |  |  | December 31, 2024 |
Compensation related accruals |  | $ | 4,368 |  |  | $ | 6,770 |
Accrued clinical trial expenses |  |  | 844 |  |  |  | 919 |
Other expenses |  |  | 2,191 |  |  |  | 2,375 |
Total accrued liabilities |  | $ | 7,403 |  |  | $ | 10,064 |

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration